Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc.
Launch date
Employees
Market cap
€239m
Enterprise valuation
€76m (Public information from Sep 2024)
Share price
$11.39 ENTA
Watertown Massachusetts (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 122m | 97.1m | 86.2m | 79.2m | 71.2m | 73.6m | 72.1m |
| % growth | (40 %) | (21 %) | (11 %) | (8 %) | (10 %) | 3 % | (2 %) |
| EBITDA | (41.6m) | (110m) | (121m) | (123m) | (112m) | (128m) | - |
| % EBITDA margin | (34 %) | (113 %) | (140 %) | (156 %) | (157 %) | (174 %) | - |
| Profit | (36.2m) | (79.0m) | (122m) | (134m) | (112m) | (120m) | (154m) |
| % profit margin | (30 %) | (81 %) | (141 %) | (169 %) | (157 %) | (163 %) | (213 %) |
| EV / revenue | 7.5x | 11.8x | 12.5x | 3.0x | 3.8x | 3.7x | 3.8x |
| EV / EBITDA | -22.1x | -10.5x | -8.9x | -1.9x | -2.4x | -2.1x | - |
| R&D budget | 137m | 174m | 165m | 164m | - | - | - |
| R&D % of revenue | 112 % | 179 % | 191 % | 206 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$5.1m | Series A | ||
$20.0m | Series B | ||
| N/A | N/A | - | |
| N/A | $18.3m | Series E | |
$12.0m | Late VC | ||
| N/A | $20.0m | Early VC | |
N/A | Seed | ||
| N/A | N/A | IPO | |
$9.2m | Early VC | ||
| Total Funding | €76.9m | ||
Recent News about Enanta Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.